Cannabis in Parkinson’s Disease — The patient’s perspective versus clinical trials: a systematic literature review

23Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.

Abstract

Cannabis and cannabinoids are often considered in the treatment of Parkinson’s Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.

Cite

CITATION STYLE

APA

Figura, M., Koziorowski, D., & Sławek, J. (2022). Cannabis in Parkinson’s Disease — The patient’s perspective versus clinical trials: a systematic literature review. Neurologia i Neurochirurgia Polska. Via Medica. https://doi.org/10.5603/PJNNS.a2022.0004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free